Literature DB >> 21548475

Sorafenib for HCC: a pragmatic perspective.

Nataliya Razumilava1, Gregory J Gores.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21548475

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  3 in total

1.  6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.

Authors:  Yanning Liu; Guohua Lou; John T Norton; Chen Wang; Irawati Kandela; Shuai Tang; Nathaniel I Shank; Pankaj Gupta; Min Huang; Michael J Avram; Richard Green; Andrew Mazar; Daniel Appella; Zhi Chen; Sui Huang
Journal:  FASEB J       Date:  2017-08-17       Impact factor: 5.191

2.  Prediction and analysis of weighted genes in hepatocellular carcinoma using bioinformatics analysis.

Authors:  Qifan Zhang; Shibo Sun; Chen Zhu; Yujian Zheng; Qing Cai; Xiaolu Liang; Haorong Xie; Jie Zhou
Journal:  Mol Med Rep       Date:  2019-02-04       Impact factor: 2.952

3.  Long non-coding RNA Myd88 promotes growth and metastasis in hepatocellular carcinoma via regulating Myd88 expression through H3K27 modification.

Authors:  Xiaoliang Xu; Yin Yin; Junwei Tang; Yu Xie; Zhuo Han; Xudong Zhang; Qiaoyu Liu; Xihu Qin; Xinli Huang; Beicheng Sun
Journal:  Cell Death Dis       Date:  2017-10-12       Impact factor: 8.469
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.